©  ViroCure 2018

#503 AceTwinTower1cha Gurodigital complex

(Or: 212-1 Guro-dong, Guro-gu)

Gurodong, Seoul, Republic of Korea. 08381

Tel: +82 2 861 0316

Fax: +82 2 861 0315

ViroCure is developing multiple virus platforms for cancer therapeutics & vaccine development.

Our viruses selectively infect and kill cancer cells, and activate anti-cancer immune responses. Our technology replicates profusely in cancer cells, with negligible effects on normal cells.
RC402

A naturally occuring reovirus originally isolated from a healthy child, which pre-clinical studies have shown to be highly effective at fighting metastatic gastric cancer and lung cancer (RC402).

  • Proven to be long-lasting, safe, & stable for human subjects

  • Improved cytopathic effect without additional arming in specific tumor types e.g. gastric, colorectal, melanoma

  • Enhanced priming effect to enhance the efficacy of ICI

  • Anti-angiogenic effect to kill tumors

  • Applicable for both local and systemic administration

  • Usage patent granted in Korea, China, & Japan

  • Clinical trial scheduled in Australia in 2019 for liver-metastasized solid tumors

  • Targets cancers prevalent in China

RP116

A naturally occuring reovirus which preliminary research has shown to be highly effective at fighting oral cancers, salivary gland cancer, soft tissue sarcoma, melanoma, etc. (RP116)

  • First-in-the-world, proprietary oncolytic virus with modification of sigma1, a major immunogenic capsid protein of RC402

    • Notable efficacy in certain cancer types, especially in rare cancers, e.g. head & neck, melanoma, & soft-tissue sarcoma

  • Applicable to immuno-competent and compromised tumor patients, e.g. pregnant women, children, AIDS patients, etc.

  • Enhanced priming effect to enhance the efficacy of ICI

  • Patents granted in the USA / Challenge to global market

MC509

A naturally occuring rabbit-specific poxvirus, originally isolated from a Brazillian rabbit species. Not known to cause diseases outside of rabbit species. In pre-clinical studies, MC509 has been highly oncolytic against tumor-bearing animals. 

  • Different backbone from other viruses

    • Systemic administration possible without generating neutralizing antibodies

  • Using gene editing to create new viral agents

    • Manipulation of tumor micro-environment for immune evasion, boosting, etc.

    • Creation of cancer vaccines

  • Targets global pharma for licensing-out & partnership

SC717

A naturally occuring squirrel-specific poxvirus originally isolated from a grey squirrel. Not known to cause diseases outside of squirrel species. In pre-clinical studies, SC717 has been highly oncolytic against tumor-bearing animals.

  • Oncolytic viral activity discovered and patented by Virocure

  • Systemic administration possible without generating neutralising antibody

  • Using gene editing to create new viral agents

    • Manipulation of tumor micro-environment for immune evasion, boosting, etc.

    • Creation of cancer vaccines

  • Targeting global pharma for licensing-out & partnership

Development Pipeline

Virus Platform                Discovery Research                Preclinical                Phase I                Phase II/III

RC402                        Gastric, lung, & colorectal cancer                                 

Phase I begins 2H 2019. Various options planned for completion, e.g. licensing out

RP116                         Head & neck cancer, prostrate cancer          

Patent registered in the United States. First target is for orphan drug designation.

MC509-XX                 Solid cancers                                  

Engineered virus (currently in development). Patents registered for cancer treatment in Korea, China, & Japan.

SC717                         Solid cancers                        

Engineered virus (currently in development). Patents registered for cancer treatment in Korea.

Combination therapies                                            

First-in-class, patented, virus+ICI, virus+virus. Various combination therapies with ICI and other specific viruses are currently in development.

Last updated 25 July 2019.